Xenotransplantation Market Size, Share, and Industry Analysis, By Product (Heart, Kidney, and Others), By Source (Porcine, Bovine, and Others), By End-user (Hospitals, Transplantation Centers, and Others), and Regional Forecast, 2025-2032

Xenotransplantation is the transplantation, implantation, or infusion of live cells, tissues, or organs from one species to another, often from an animal source into a human recipient. Across healthcare, organ transplantation is well-established for the treatment of patients with end-stage organ failure. Additionally, various research initiatives have indicated that transplanting cells and tissues could be beneficial for conditions such as end-stage organ failure, neural disorders, and diabetes. In spite of this, there is a huge organ shortage that limits the transplantation of organs. In the past, xenotransplantation of kidneys, hearts, liver, corneas, and skin was attempted to address these organ shortages. However, immune rejection and ethical concerns have appeared to be major obstacles to xenotransplantation

Amid these, in 2021, the first xeno kidney grown in a genetically altered pig was attached to humans without immune rejection. This breakthrough is changing the landscape of xenotransplantation across the globe. The growth of xenotransplantation is expected to emerge in the coming years. The current global regulatory landscape and notable clinical advances are expected to be key factors for market growth.

Additionally, ongoing R&D investments in clinical and pre-clinical studies are anticipated to grow the market over the projected years. Technological advancements such as CRISPR CAS for gene knockout and approval of transgenic porcine for organ transplantations are expected to support ongoing studies across the globe. Furthermore, key players' focus on developing new transgenic animals and tools for gene alteration is propelling the market growth.

• In June 2023, South Korean genome editing developer ToolGen Inc. collaborated with Lartbio Technology, a Seoul-based transgenic animal development company, for the development of a transgenic cow to produce artificial blood.

Moreover, the rising number of industry and academic collaborations and players’ strategic acquisition of clinical-stage companies are expected to boost market growth in the next few years.

The COVID-19 pandemic substantially impacted the market due to the travel restrictions and global lockdowns. The number of patients visiting hospitals and surgeries declined during the pandemic, which further hampered the xenotransplantation market. The post-pandemic relaxation of restrictions and the growth in genetic engineering significantly increased the xenotransplantation market's growth.

Segmentation

KEY INSIGHTS

The report covers the following key insights:

• Regulatory Landscape for Xenotransplantation by Key Country/Region
• Pipeline Analysis by Key Players
• Organ Transplantation Procedures by Key Country/Region
• Key Industry Developments: Mergers, Acquisitions, and Partnerships
• Impact of COVID-19 on the Market

Analysis by Xeno Product

In terms of xeno product, the market is classified into heart, kidney, and others. The kidney segment held a significant revenue in the global market. The growth of the segment can be attributed to the rising number of kidney failures and the increased number of kidney transplants across the globe. The shortage of human donors is anticipated to increase the growth of xenotransplantation. The rising number of clinical trials and advancements in genetic engineering further propel the segment's growth.

• For instance, in January 2023, Makana Therapeutics received a patent for its TKO pig to be used in kidney transplantation. It is a triple knockout pig that effectively fits the human recipient's immune system.

The heart segment held considerable revenue in the global market. Growth in the prevalence of chronic heart diseases and congestive heart failure is anticipated to drive the chances of xenotransplantation and market growth in the near future.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for a significant share of the market in 2023. The region's high prevalence of kidney and other organ failures and greater demand for organ transplantation are anticipated to drive the segment growth. Furthermore, the presence of major players and rapidly growing transplantation numbers is expected to drive the segment growth. Moreover, the rising collaborations between universities and organ transplantation companies are expected to result in more compatible organ production, and market growth is expected in the near future.

• For instance, between 2021 and 2023, 10 xenotransplantation procedures using United Therapeutics' xenohearts and xenokidneys were performed in the U.S. in living and brain-dead human recipients.

Asia Pacific is expected to witness rapid growth in the coming years. Ongoing R&D activities in the region to produce transgenic organs and increasing investments are the key factors expected to drive the segment growth. Additionally, the government initiatives in Japan and South Korea to create guidelines for xenotransplantation, the increasing prevalence of end-stage renal disease & organ failure are the factors anticipated to drive the market growth in the region.

Key Players Covered

The report includes key players, such as United Therapeutics Corporation, Makana Therapeutics, eGenesis, NZeno, OPTIPHARM Co., Ltd., XenoTherapeutics Foundation, and CareDx Inc.

Key Industry Developments

• In February 2024, PorMedTec Co., a Kawasaki-based company, developed three genetically modified piglets for kidney transplantation to prevent rejection in human transplants.
• In December 2023, United Therapeutics Corporation acquired Miromatrix Medical Inc. to expand xenotransplantation. Miromatrix Medical Inc. specializes in bioengineered kidneys and livers.
• In June 2023, Makana Therapeutics was awarded an Artificial Kidney Phase II Prize from KidneyX to continue the development of its genetically engineered triple knockout donor pigs for use in kidney transplantation.